Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2009 Dec 9;87(3):303–310. doi: 10.1038/clpt.2009.217

Figure 1.

Figure 1

Improvement in characteristic erythematous epoprostenol rash in subject 4. At baseline (left) and after 119 days (16 weeks) of sorafenib administration (right).